Stock Events

Stock Events

InflaRx N.V. 

$2.22
47
-$0.01-0.45% Friday 20:00
+$0.00+0%Friday 20:00After hours

Statistics

Day High
2.22
Day Low
2.17
52W High
2.95
52W Low
0.798
Volume
8,647
Avg. Volume
-
Mkt Cap
327.16M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.25
-0.19
-0.13
-0.06
Expected EPS
-0.06456026892
Actual EPS
N/A

Financials

-154,378.99%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
34,247.57Revenue
-52.87MNet Income

Analyst Ratings

9.67Average Price Target
The highest estimate is 14.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IFRX. It's not an investment recommendation.
Alphabet
8
GOOGL
Amazon
7
AMZN
PepsiCo
7
PEP
Microsoft
6
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is involved in discovering, inventing, developing, manufacturing, and commercializing medicines for treating various medical conditions, including inflammatory conditions.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. develops and markets drugs to treat inflammatory and infectious diseases, directly competing with InflaRx's product pipeline.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie Inc. has a strong portfolio in immunology and inflammatory diseases, making it a direct competitor to InflaRx in the biopharmaceutical sector.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. is a biotechnology company with products targeting inflammatory diseases, competing in the same therapeutic areas as InflaRx.
Biogen
BIIB
Mkt Cap32.28B
Biogen Inc. focuses on developing therapies for neurological and neurodegenerative diseases, some of which involve inflammatory pathways, indirectly competing with InflaRx.
Novartis
NVS
Mkt Cap292.35B
Novartis AG has a broad portfolio including treatments for autoimmune and inflammatory diseases, making it a competitor in the same market as InflaRx.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including inflammation, competing with InflaRx's therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson operates in the pharmaceutical, medical devices, and consumer health sectors, with a significant presence in the immunology market, competing with InflaRx in the area of inflammatory diseases.

About

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Show more...
CEO
Niels C. Riedemann
Employees
65
Country
Netherlands
ISIN
NL0012661870
WKN
000A2H7A5

Listings

MX
MX
IFRXN.MX
STU
DE
IF0.STU
MU
DE
IF0.MU
F
DE
IF0.F

0 Comments

Share your thoughts

FAQ

What is InflaRx N.V. stock price today?▼
The current price of IFRX is $2.22 USD — it has decreased by -0.45% in the past 24 hours. Watch InflaRx N.V. stock price performance more closely on the chart.
What is InflaRx N.V. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange InflaRx N.V. stocks are traded under the ticker IFRX.
Is InflaRx N.V. stock price growing?▼
IFRX stock has fallen by -0.45% compared to the previous week, the month change is a +25.42% rise, over the last year InflaRx N.V. has showed a +34.55% increase.
What is InflaRx N.V. market cap?▼
Today InflaRx N.V. has the market capitalization of 327.16M
When is the next InflaRx N.V. earnings date?▼
InflaRx N.V. is going to release the next earnings report on November 06, 2026.
What were InflaRx N.V. earnings last quarter?▼
IFRX earnings for the last quarter are -0.1 USD per share, whereas the estimation was -0.07 USD resulting in a -54.29% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is InflaRx N.V. revenue for the last year?▼
InflaRx N.V. revenue for the last year amounts to 34,247.57 USD.
What is InflaRx N.V. net income for the last year?▼
IFRX net income for the last year is -52.87M USD.
How many employees does InflaRx N.V. have?▼
As of September 05, 2026, the company has 65 employees.
In which sector is InflaRx N.V. located?▼
InflaRx N.V. operates in the Health & Wellness sector.
When did InflaRx N.V. complete a stock split?▼
InflaRx N.V. has not had any recent stock splits.
Where is InflaRx N.V. headquartered?▼
InflaRx N.V. is headquartered in Jena, Netherlands.